MEDIFAST, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.71 USD | +0.63% |
|
+3.91% | -49.85% |
| Feb. 20 | Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 20 | Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024 |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -49.85% | 363M | C- | ||
| +8.20% | 7.78B | D+ | ||
| +0.34% | 7.38B | C- | ||
| +10.20% | 6.52B | - | ||
| -8.10% | 3.67B | D | ||
| -14.57% | 1.17B | - | - | |
| +8.34% | 934M | - | ||
| -42.27% | 879M | B+ | ||
| -18.90% | 836M | C+ | ||
| -16.45% | 802M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.
